patient treated with DMARD

PreclinicalSmall molecule

UUniversity Hospital, Toulouse

patient treated with DMARD is one of 5 small molecule programs targeting Hydrocephalus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HydrocephalusActive, not recruiting

HydrocephalusPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Hydrocephalus

#DrugCompanyPhaseTrials

Imdur

OOmnivium

Approved

—2

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 3

Rapamycin

MMaastricht Radiation Oncology

Phase 2

1 4

Rapamune

PPrism Pharmaceuticals

Preclinical

1 5

patient treated with DMARD

UUniversity Hospital, Toulouse

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cancer1 trial

Abatacept and the Risk of Cancer: a Case Non-case Analysis in VigiBase

Unknown status·UUniversity Hospital, Toulouse··NCT03980639·594,226 enrolled

Hydrocephalus1 trial

Cerebrospinal Fluid Proteome in Hydrocephalus

Completed·UUniversity Hospital, Toulouse·N/A·NCT02016352·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for patient treated with DMARD. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — patient treated with DMARD compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for patient treated with DMARD. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Toulouse company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Toulouse

patient treated with DMARD

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cancer1 trial

Hydrocephalus1 trial

References

Drug Info

Quick Facts

Related News